Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide

被引:11
|
作者
Boytsov, Natalie [1 ]
Zhang, Xiang [1 ]
Sugihara, Tomoko [2 ]
Taylor, Kathleen [1 ]
Swindle, Ralph [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] InVentiv Hlth Clin, Princeton, NJ USA
关键词
Comparative effectiveness; Healthcare resource utilization; Osteoporosis; Teriparatide; BONE-MINERAL DENSITY; PERSISTENCE; ADHERENCE; SCORE;
D O I
10.1185/03007995.2015.1066765
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare fractures and fracture-related resource utilization (RU) among patients with a recent fracture and treated with teriparatide (TPTD) to a matched cohort of patients not treated with TPTD (non-TPTD). Research design and methods: Women aged 50 years or older initiating TPTD (N = 5314; index date between 1 January 2007 and 31 December 2012) were identified in an insurance claims database. Patients with fragility fracture (hip, pelvis, clavicle, humerus, wrist, leg or spine) during the 12 months prior to the index date (N = 1164) were selected to control for unmeasured confounding due to absence of bone mineral density test levels. TPTD patients were matched to the non-TPTD cohort using propensity score and exact matching (N = 912). Relative risk (RR) of fracture and fracture-related RU were estimated by Cox proportional hazard modeling, adjusted for potential fracture risk factors. Results: Fractures were observed in 4.6%, 8.6%, 10.3%, and 11.3% of TPTD patients and in 9.2%, 15.2%, 19.2% and 21.7% of non-TPTD patients over 6, 12, 18, and 24 months, respectively. The adjusted RR reduction in TPTD was 36% (RR = 0.64, 95% CI: 0.44-0.94) during 6 months, 27% (RR = 0.73, 95% CI: 0.54-0.97) during 12 months, 28% (RR = 0.72, 95% CI: 0.55-0.93) during 18 months, and 28% (RR = 0.72, 95% CI: 0.56-0.92) during 24 months versus matched non-TPTD patients. Fracture-related RU followed a similar trend to that observed for fracture risk. Conclusions: This real-world study found TPTD to be more effective in reducing risk of fragility fractures as early as 6 months with continuous treatment benefit up to 24 months compared to a matched non-TPTD cohort. TPTD patients experienced lower rates of fracture-related RU than non-TPTD patients. Key study limitations include the inability to confirm reported diagnostic and procedural codes and the absence of uninsured and individually insured patients in the claims database.
引用
收藏
页码:1665 / 1675
页数:11
相关论文
共 50 条
  • [21] Medication review of teriparatide subcutaneous injection in osteoporotic patients
    Ahmad, S
    Adams, KRH
    Adams, M
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 592 - 592
  • [22] USE OF TERIPARATIDE THERAPY IN OSTEOPOROTIC PATIENTS: AN ESI EXPERIENCE
    Malik, K.
    Gupta, S.
    Gupta, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S478 - S478
  • [23] Higher Rates of Union in Older Patients with Type 2 and Type 3 Odontoid Fractures Treated with Teriparatide
    Sietsema, Debra
    Merrick, Michael
    Smith, Casey
    Chen, Tan
    Russo, Scott
    Jones, Clifford
    Stubbart, James
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [24] Less Falls in Osteoporosis Patients treated with Teriparatide: A Meta-Analysis
    Moeckel, Luis
    [J]. OSTEOLOGIE, 2020, 29 (01) : 31 - 38
  • [25] ADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE
    Camacho, Pauline M.
    Mazhari, Alaleh M.
    Wilczynski, Cory
    Kadanoff, Ruth
    Mumm, Steven
    Whyte, Michael P.
    [J]. ENDOCRINE PRACTICE, 2016, 22 (08) : 941 - 950
  • [26] HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE
    Osca Guadalajara, M.
    Vivas Consuelo, D.
    Caballer Tarazona, V
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A939 - A939
  • [27] CAN PATIENTS WITH CHRONIC KIDNEY DISEASE BE TREATED WITH A COMBINATION OF TERIPARATIDE AND DENOSUMAB?
    Miskic, K.
    Miskic, B.
    Cosic, V.
    Jakab, J.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S510 - S510
  • [28] Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures
    Gallagher, JC
    Genant, HK
    Crans, GG
    Vargas, SJ
    Krege, JH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03): : 1583 - 1587
  • [29] Outcomes from a patient educational program in postmenopausal osteoporotic women treated with teriparatide
    Larrainzar, R.
    Aragon, A.
    Rentero, M.
    Lopez, A.
    Casillas, M.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S216 - S216
  • [30] Reduction of the risk of new vertebral fractures in postmenopausal women treated with teriparatide
    Carlino, G.
    [J]. BONE, 2009, 44 (02) : S431 - S431